deltatrials
Completed INTERVENTIONAL NCT06409182

A Prospective Pilot Study to Evaluate the Diagnostic Performance of a Wireless Sensor Capsule in Detection of UGIB (HemoPill)

A Prospective Pilot Study to Evaluate the Diagnostic Performance of a Wireless Sensor Capsule in Detection of Upper Gastrointestinal Bleeding

Sponsor: Chinese University of Hong Kong

Conditions UGI Bleed
Interventions Hemopill
Updated 4 times since 2024 Last updated: Apr 20, 2026 Started: Dec 19, 2023 Primary completion: Apr 22, 2024 Completion: Dec 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates UGI Bleed and is currently completed. Chinese University of Hong Kong leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Study Description(click to expand)

It is a single-center, prospective study, which will be conducted in a tertiary academic hospital (Prince of Wales Hospital). All subjects will undergo a paired examination of HemoPill® acute capsule and oesophago-gastro-duodenoscopy (OGD).

It is a single-center, prospective study, which will be conducted in a tertiary academic hospital (Prince of Wales Hospital). All subjects will undergo a paired examination of HemoPill® acute capsule and oesophago-gastro-duodenoscopy (OGD).

Status Flow

~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Apr 2026 · 20 months · monthly snapshotRecruitingApr 23, 2026 – present · 3 months · daily APICompleted

Change History

4 versions recorded
  1. Apr 23, 2026 — Present [daily]

    Completed

    Status: RecruitingCompleted · Phase: NANone

  2. Sep 2024 — Apr 2026 [monthly]

    Recruiting NA

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting NA

  4. Jun 2024 — Jul 2024 [monthly]

    Recruiting NA

    First recorded

Dec 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

It is a single-center, prospective study, which will be conducted in a tertiary academic hospital (Prince of Wales Hospital). All subjects will undergo a paired examination of HemoPill® acute capsule and oesophago-gastro-duodenoscopy (OGD).

Contact Information

Sponsor contact:
  • Chinese University of Hong Kong
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations